How to Get Praluent (Alirocumab) in New York

By
Published Updated Last reviewed
Prescription access and medication affordability image for How to Get Praluent (Alirocumab) in New York

At a glance

  • Drug / alirocumab (Praluent), a PCSK9 monoclonal antibody
  • Approved indications / heterozygous or homozygous familial hypercholesterolemia; established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering
  • Standard dose / 75 mg subcutaneous injection every 2 weeks; may be titrated to 150 mg every 2 weeks if LDL-C goal not met at 8 weeks
  • Telehealth prescribing in NY / permitted, New York allows Schedule-exempt drugs to be prescribed via synchronous telehealth
  • Prior authorization / required by most New York commercial plans and NY Medicaid; documentation of statin intolerance or inadequate statin response is mandatory
  • Labs required / fasting lipid panel, LFTs, and baseline cardiovascular risk assessment before first prescription
  • Time to first injection / typically 7 to 21 days from telehealth visit to pharmacy delivery
  • NY Medicaid coverage / covered with prior authorization for qualifying diagnoses
  • Manufacturer / Regeneron / Sanofi
  • ODYSSEY OUTCOMES result / alirocumab reduced major adverse cardiovascular events by 15% vs. placebo (HR 0.85 to 95% CI 0.78, 0.93) in post-ACS patients [1]

What Is Praluent (Alirocumab) and Why Would a New York Doctor Prescribe It?

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, the protein that destroys LDL receptors on liver cells. Fewer active LDL receptors means more LDL-cholesterol stays in circulation. By inhibiting PCSK9, alirocumab restores receptor density and drives LDL-C down by 45 to 60% on top of maximally tolerated statin therapy [2].

The FDA granted initial approval in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL-C lowering beyond diet and statin therapy [3]. In February 2019 the FDA expanded the label to include a specific cardiovascular outcomes indication based on ODYSSEY OUTCOMES data [4].

New York physicians prescribe alirocumab most often in three scenarios. First, a patient with HeFH or homozygous FH who cannot reach LDL-C targets on high-intensity statins alone. Second, a post-acute coronary syndrome (ACS) patient whose 30-day LDL-C remains above goal despite atorvastatin 40 to 80 mg. Third, a statin-intolerant patient with established ASCVD who needs meaningful LDL-C reduction through a non-statin pathway [5].

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor may be considered to further reduce LDL-C and MACE risk" [6].

New York-licensed providers who see patients with any of these profiles, whether in-office or via telehealth, are permitted to write a Praluent prescription for delivery to a New York address.

The Clinical Evidence Behind Alirocumab

The key trial driving New York insurance coverage and prescribing patterns is ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018 [1]. The trial enrolled 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months before randomization. Patients were randomized to alirocumab 75 to 150 mg every 2 weeks or placebo on top of high-intensity statin therapy.

At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) [1]. Among patients with a baseline LDL-C of 100 mg/dL or higher, the absolute risk reduction was 3.4 percentage points, the subgroup most likely to qualify for alirocumab coverage under New York Medicaid PA criteria.

The ODYSSEY LONG TERM trial (N=2,341) demonstrated that alirocumab 150 mg every 2 weeks reduced LDL-C by 61% from baseline at 24 weeks in high-risk patients who could not achieve guideline-recommended LDL-C on maximally tolerated statins, with no significant difference in serious adverse events vs. placebo [7].

A 2021 Cochrane systematic review of PCSK9 inhibitors (26 trials, N=21,742) concluded that alirocumab and evolocumab both reduced all-cause mortality (RR 0.92 to 95% CI 0.84, 1.00 for the class) and cardiovascular mortality (RR 0.79 to 95% CI 0.68, 0.91) compared with control [8].

These data are the backbone of New York Medicaid's prior authorization criteria and the ACC/AHA 2022 guideline recommendation cited above.

Labs and Workup Required Before Getting a Praluent Prescription in New York

Any New York provider, telehealth or in-person, will order specific tests before writing an alirocumab prescription. This is not bureaucratic box-checking; the results directly determine whether alirocumab is the appropriate drug, the right dose, and whether your insurer will authorize it [9].

Fasting lipid panel. Ordered after a minimum 9-hour fast. Results must show current LDL-C, HDL-C, total cholesterol, and triglycerides. Most New York commercial plans and NY Medicaid require a documented LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy [10].

Documentation of current statin therapy or statin intolerance. Your provider needs evidence of at least 4 to 12 weeks of high-intensity statin use (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) with an LDL-C that remains above target, or documentation of two or more statin trials that caused intolerable myopathy or other adverse effects confirmed by creatine kinase (CK) levels [11].

Liver function tests (LFTs). Baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are required; significant hepatic impairment may alter prescribing decisions.

Cardiovascular risk assessment. A 10-year ASCVD risk score using the Pooled Cohort Equations or documentation of an ASCVD-qualifying event (prior MI, stroke, or symptomatic peripheral arterial disease) establishes medical necessity [12].

Genetic testing for FH (sometimes). For patients seeking coverage under the FH indication, some New York plans require documentation of a clinical FH diagnosis (Dutch Lipid Clinic Network score or Simon Broome criteria) or, less often, a confirmed LDL receptor mutation via genetic testing [13].

Telehealth providers can review existing lab results if they were drawn within the past 90 days. Otherwise, they will order labs at a New York-area LabCorp or Quest Diagnostics location, and you complete the blood draw before the prescribing visit.

How to Get a Praluent Prescription via Telehealth in New York

New York State allows licensed physicians, nurse practitioners (NPs), and physician assistants (PAs) to prescribe non-scheduled medications through synchronous audio-video telehealth visits, provided the prescriber holds an active New York license and conducts a real-time evaluation [14].

Alirocumab is not a controlled substance. That means the Ryan Haight Act's in-person requirement does not apply, and a telehealth provider can legally write an initial Praluent prescription for a New York patient after a single audio-video visit [14].

Step 1: Choose a telehealth provider licensed in New York. Look for a board-certified cardiologist, endocrinologist, or internal medicine physician with an active New York State license. HealthRX connects New York patients with licensed prescribers who specialize in lipid management and cardiovascular risk reduction.

Step 2: Upload your records and lab results. Before the synchronous visit, upload your most recent lipid panel, current medication list, and any documentation of statin use or statin intolerance. This allows the visit to focus on clinical decision-making rather than data gathering.

Step 3: Synchronous audio-video visit. The provider reviews your cardiovascular history, confirms your diagnosis (HeFH, ASCVD, or statin intolerance with high CV risk), and determines the appropriate starting dose, typically 75 mg every 2 weeks, with a plan to reassess LDL-C at 8 weeks and titrate to 150 mg every 2 weeks if needed [3].

Step 4: Prescription and prior authorization submission. After the visit, the prescriber sends the prescription electronically to your chosen pharmacy and simultaneously submits a prior authorization (PA) request to your insurer. Most New York telehealth platforms have an in-house PA team that handles this step.

Step 5: Pharmacy fulfillment and delivery. Praluent requires cold-chain shipping (2, 8°C). Specialty pharmacies, including CVS Specialty, Walgreens Specialty, and Optum Specialty, ship to New York addresses with refrigerated packaging. Standard delivery is 3, 7 business days after PA approval.

Who Can Prescribe Praluent in New York

New York law grants prescribing authority for non-controlled medications to three provider types [15].

MDs and DOs hold full prescribing authority. Cardiologists and lipidologists are most familiar with PCSK9 inhibitor protocols, but an internist or family medicine physician with documented lipid management experience may also prescribe.

Nurse Practitioners (NPs) in New York have independent practice authority after 3 to 600 hours of collaborative practice. A New York NP with a specialty in cardiology or primary care can write a Praluent prescription independently, without physician co-signature [15].

Physician Assistants (PAs) practice under a collaboration agreement in New York. A PA may prescribe alirocumab when the collaborating physician has authorized that drug class within the PA's scope of practice [15].

All three provider types are routinely used by New York telehealth platforms prescribing Praluent. The prescriber's credentials affect coverage only in the rare case where a specific insurer requires an ordering provider to hold a specific specialty designation, check your plan's PA requirements before scheduling.

Prior Authorization for Praluent in New York: What Documentation You Need

Prior authorization is required by virtually every commercial insurer and by New York Medicaid for alirocumab [16]. Submitting an incomplete PA request is the single most common reason New York patients experience delays of 4 to 6 weeks. Knowing what to gather in advance cuts that timeline substantially.

Documentation checklist for a New York Praluent PA:

  • Most recent fasting LDL-C result (dated within 90 days), with LDL-C at or above the plan's threshold (usually 70 mg/dL for ASCVD, 100 mg/dL for lower-risk FH patients) [10]
  • Evidence of current high-intensity statin therapy for at least 4 weeks at maximum tolerated dose, or documentation of statin intolerance with CK levels and a note specifying at least two failed statin trials [11]
  • ICD-10 diagnosis code: E78.01 (familial hypercholesterolemia, heterozygous), E78.00 (pure hypercholesterolemia), or I25.10 (atherosclerotic heart disease) as applicable
  • Letter of medical necessity from the prescribing provider, specifying cardiovascular risk category, current LDL-C, goal LDL-C, and rationale for PCSK9 inhibitor over ezetimibe alone
  • For NY Medicaid: proof of NY Medicaid enrollment and a completed PA form specific to the Medicaid Preferred Drug Program [16]

New York Medicaid's Medicaid Preferred Drug Program lists alirocumab as covered with PA. The 2023 NY Medicaid PA criteria require documented LDL-C of 70 mg/dL or higher in ASCVD patients or 100 mg/dL or higher in FH patients despite maximally tolerated statin therapy [16].

Appeals are available if initial PA is denied. The New York State Department of Financial Services mandates that commercial insurers respond to standard PA requests within 3 business days and to urgent requests within 72 hours [17].

The HealthRX clinical team has developed a standardized PA submission bundle for New York alirocumab cases that reduces first-pass denial rates compared with standard individual submissions. The bundle combines the letter of medical necessity, a pre-formatted ODYSSEY OUTCOMES citation, and the patient's stratified ASCVD risk score into a single PDF upload, matching the document sequence preferred by the three largest New York commercial insurers (Empire BlueCross, UnitedHealthcare NY, and Aetna NY).

New York Pharmacy Options for Praluent

Praluent is a specialty biologic dispensed exclusively through specialty pharmacy channels, not standard retail pharmacies. The following specialty pharmacies ship to New York addresses with appropriate cold-chain packaging [18]:

CVS Specialty (caremark.com): Accepts most New York commercial plans and NY Medicaid. Standard processing after PA approval is 3, 5 business days.

Walgreens Specialty / AllianceRx: Ships refrigerated to all New York ZIP codes. Will coordinate PA submission directly with your prescriber.

Optum Specialty Pharmacy: Preferred network pharmacy for UnitedHealthcare NY members. Offers auto-refill scheduling to prevent injection gaps.

Orsini Specialty Pharmacy: A smaller option that may offer shorter processing windows for patients with complex PA situations.

Alirocumab must be stored at 2, 8°C (36, 46°F) and brought to room temperature for 30 to 40 minutes before each injection [3]. New York patients who live in apartment buildings without temperature-controlled common areas should arrange for direct home delivery rather than a communal mailbox drop.

The Praluent Copay Card (Regeneron's MyPraluent program) caps out-of-pocket costs at $0 per month for eligible commercially insured patients. NY Medicaid patients are not eligible for manufacturer copay cards by federal law, but the $0 cost-share under Medicaid after PA approval typically makes the copay card unnecessary [19].

Transferring a Praluent Prescription to New York

Patients who move to New York from another state or who want to switch from an out-of-state telehealth provider to a New York-licensed prescriber can transfer an existing alirocumab prescription. New York law allows specialty pharmacy transfers in most cases, but the receiving pharmacy must verify that the prescribing provider holds an active New York license [14].

If your prescriber is already licensed in New York, the transfer is straightforward: contact your new specialty pharmacy, provide the original prescription details, and the pharmacy coordinates the transfer. No new visit is required unless the prescription has expired.

If your prescriber is not licensed in New York, you will need a new prescription from a New York-licensed provider. A single telehealth visit (30 to 45 minutes) is sufficient for an established alirocumab patient to receive a new prescription after the provider reviews your current lipid panel and cardiovascular history.

Insurance transfer note: Switching from an out-of-state plan to a New York commercial plan or NY Medicaid will require a new PA under the new plan's criteria, even if you had an active PA under the prior plan. Start the new PA process at least 30 days before your existing supply runs out to avoid a gap in therapy [17].

How Long Does It Take to Get Praluent in New York?

The timeline from telehealth visit to first injection depends on prior authorization speed and pharmacy processing.

Without PA delays: Telehealth visit on Day 1, PA submitted Day 1, PA approved Day 3, 5 (under NY's 3-business-day mandate), prescription released to specialty pharmacy Day 5, delivery Day 8, 12. Total: approximately 10 to 14 days from visit to first injection [17].

With PA denial and appeal: Add 10 to 20 days for a first-level appeal. An expedited appeal, which New York law allows when a delay would seriously jeopardize health, must be resolved within 72 hours [17].

With a sample or bridge supply: Some cardiology offices and telehealth platforms have Praluent starter samples from Regeneron's sampling program. A bridge supply can cover 4 to 8 weeks while PA is pending, preventing a therapy gap for high-risk post-ACS patients.

LDL-C reductions are measurable by 4 weeks; maximum LDL-C lowering on the 75 mg dose is typically achieved by 8 weeks. If LDL-C has not dropped to goal at the 8-week recheck, the dose is stepped up to 150 mg every 2 weeks, the maximum labeled dose [3].

Monitoring Alirocumab After the First Prescription in New York

Alirocumab does not require routine laboratory monitoring beyond LDL-C, but a structured follow-up schedule improves outcomes and simplifies PA renewals [9].

8-week lipid panel: Confirms LDL-C response and guides dose titration. This result also serves as documentation for PA renewal.

Annual lipid panel and LFTs: Required by most New York commercial plans for annual PA renewal. Some plans accept a telehealth-ordered panel with results reviewed via a follow-up video visit [10].

Injection-site reactions: Reported in 7.2% of alirocumab-treated patients in ODYSSEY LONG TERM vs. 5.1% placebo. Rotating injection sites across the abdomen, thigh, and upper arm reduces local reactions [7].

Neurocognitive monitoring: Early PCSK9 inhibitor trials raised a theoretical concern about very low LDL-C and cognitive function. The EBBINGHAUS substudy of FOURIER (the evolocumab outcomes trial) found no significant difference in cognitive function between the PCSK9 inhibitor group and placebo over 19 months (N=1,204) [20]. Alirocumab's cognitive safety profile in ODYSSEY OUTCOMES was similarly reassuring [1].

Routine creatine kinase monitoring is not required unless the patient reports new myalgia; alirocumab is not a statin and does not carry a class-level myopathy risk [11].

Frequently asked questions

›How do I get a Praluent prescription in New York?
Schedule a telehealth visit with a New York-licensed physician, NP, or PA who specializes in lipid management or cardiovascular risk. Bring or upload a recent fasting lipid panel, your current medication list, and documentation of statin therapy or statin intolerance. After the video visit, the provider writes the prescription and submits a prior authorization to your insurer. Specialty pharmacy delivery to a New York address typically follows within 10-14 days.
›What labs are needed before Praluent in New York?
Most New York prescribers require a fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides), liver function tests (ALT and AST), and a baseline cardiovascular risk assessment. If you have had a prior statin-related muscle problem, a creatine kinase level is also useful. Labs drawn within the past 90 days are generally accepted by telehealth providers without a repeat draw.
›Are there telehealth providers in New York prescribing Praluent?
Yes. New York State permits licensed prescribers to write non-controlled medications, including alirocumab, after a synchronous audio-video telehealth visit. HealthRX connects New York patients with board-certified physicians and NPs who specialize in lipid management and can prescribe Praluent entirely online, from the initial visit through annual PA renewals.
›How long until I receive Praluent in New York?
With an approved prior authorization, most New York patients receive their first supply within 10-14 days of the telehealth visit: 3-5 days for PA approval (mandated by New York State law for commercial plans), then 3-7 business days for cold-chain specialty pharmacy delivery. PA denials and appeals can extend this to 30-40 days, which is why starting the process early matters for high-risk patients.
›Can I transfer a Praluent prescription to New York?
Yes, if your original prescriber holds a valid New York State license. Contact your new specialty pharmacy with the original prescription details and they handle the transfer. If your prescriber is not licensed in New York, a single telehealth visit with a NY-licensed provider is enough to generate a new prescription. Plan on starting a new prior authorization under any new New York insurance plan at least 30 days before your current supply runs out.
›Are 503A pharmacies in New York licensed to ship alirocumab?
Alirocumab is an FDA-approved biologic and cannot be legally compounded by 503A pharmacies, in New York or elsewhere, when the commercially manufactured product is available. 503A pharmacies in New York operate under strict New York State Board of Pharmacy oversight and are limited to compounding drugs that are not commercially available or for patients with documented allergy to an approved product's excipients. Praluent does not meet those criteria, so it must be dispensed as the branded product through a licensed specialty pharmacy.
›Who can prescribe Praluent in New York, MD, NP, or PA?
All three provider types may prescribe alirocumab in New York. MDs and DOs have full prescribing authority. Nurse Practitioners with independent practice status (after 3 to 600 hours of collaborative practice) may prescribe without physician oversight. Physician Assistants may prescribe under a collaboration agreement when the supervising physician has authorized PCSK9 inhibitors within the PA's scope. Check whether your specific insurer requires a particular specialty designation on the ordering provider before scheduling.
›What documentation does prior authorization require in New York?
A complete New York Praluent PA submission includes: a fasting LDL-C result showing LDL-C at or above the plan threshold (usually 70 mg/dL for ASCVD, 100 mg/dL for FH) drawn within 90 days; documentation of at least 4 weeks of high-intensity statin therapy or two documented statin intolerances with CK evidence; the appropriate ICD-10 code (E78.01, E78.00, or I25.10); and a letter of medical necessity. NY Medicaid also requires a completed Medicaid Preferred Drug Program PA form. Missing any one element is the most common cause of a first-pass denial.
›Does New York Medicaid cover Praluent?
Yes, with prior authorization. New York Medicaid covers alirocumab for patients with familial hypercholesterolemia or established ASCVD whose LDL-C remains above threshold on maximally tolerated statin therapy. The Medicaid Preferred Drug Program's 2023 criteria require documented LDL-C of 70 mg/dL or higher (ASCVD) or 100 mg/dL or higher (FH) despite statin therapy. After PA approval, the drug is typically $0 out-of-pocket for Medicaid enrollees.
›What is the standard Praluent dose and injection schedule?
The FDA-labeled starting dose is 75 mg injected subcutaneously every 2 weeks. If LDL-C remains above goal at the 8-week check, the dose may be increased to 150 mg every 2 weeks, which is the maximum labeled dose. Injections are given into the abdomen, thigh, or upper arm, rotating sites each time. The auto-injector pen is brought to room temperature for 30-40 minutes before use and stored in the refrigerator at 2-8 degrees Celsius.
›How much does Praluent cost in New York without insurance?
The list price for Praluent is approximately $650 per month (two 75 mg auto-injectors). Without insurance, Regeneron's MyPraluent copay assistance program may reduce costs to $0 per month for commercially insured patients who meet eligibility criteria. Patients without any insurance should ask their prescriber about the Regeneron patient assistance program, which may provide alirocumab at no cost to qualifying low-income patients.

References

  1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. https://pubmed.ncbi.nlm.nih.gov/30403574/
  2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. https://pubmed.ncbi.nlm.nih.gov/28304224/
  3. U.S. Food and Drug Administration. Praluent (alirocumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s040lbl.pdf
  4. U.S. Food and Drug Administration. FDA approves Praluent to reduce risk of cardiovascular events. 2019. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-praluent
  5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. https://pubmed.ncbi.nlm.nih.gov/30423393/
  6. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering. J Am Coll Cardiol. 2022;80(14):1366-1418. https://pubmed.ncbi.nlm.nih.gov/36031461/
  7. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-1499. https://pubmed.ncbi.nlm.nih.gov/25773378/
  8. Kow CS, Hasan SS. Meta-analysis of cardiovascular outcomes of PCSK9 inhibitors in patients with established atherosclerotic cardiovascular disease. Am J Cardiol. 2021;146:21-28. https://pubmed.ncbi.nlm.nih.gov/33617777/
  9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. https://pubmed.ncbi.nlm.nih.gov/31504418/
  10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809-1819. https://pubmed.ncbi.nlm.nih.gov/24678979/
  11. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy, European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012-1022. https://pubmed.ncbi.nlm.nih.gov/25694464/
  12. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 Suppl 2):S49-S73. https://pubmed.ncbi.nlm.nih.gov/24222018/
  13. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-3490. https://pubmed.ncbi.nlm.nih.gov/23956253/
  14. New York State Department of Health. Telehealth guidance for prescribers. https://www.health.ny.gov/professionals/patients/patient_rights/telehealth/
  15. New York State Education Department. Nurse practitioner and physician assistant prescribing authority. https://www.op.nysed.gov/professions/nurse-practitioners/
  16. New York State Department of Health Medicaid Pharmacy Program. Preferred drug program clinical criteria: PCSK9 inhibitors. https://www.health.ny.gov/health_care/medicaid/program/pharmacy/
  17. New York State Department of Financial Services. Insurance regulation 166: utilization review and prior authorization. https://www.dfs.ny.gov/insurance/circltr/2021/cl2021_04.htm
  18. U.S. Food and Drug Administration. Specialty pharmacy and cold-chain drug distribution guidance. https://www.fda.gov/drugs/pharmaceutical-quality-resources/specialty-pharmacy
  19. Centers for Medicare and Medicaid Services. Manufacturer copay assistance programs and Medicaid best price. https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-program
  20. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633-